Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464629 | 0.91 | TRAP1 (0.45) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL1859241 | 0.90 | HSP90B1 (0.58) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL3465502 | 0.89 | HSP90B1 (0.43) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL1857582 | 0.88 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL15609506 | 0.88 | HSP90AB1 (0.42) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL15609449 | 0.88 | HSP90B1 (0.42) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL3122396 | 0.88 | ADORA2A (0.49) | HSP90AA1HSP90AB1HSP90B1ADORA2AADORA1 | |
| SCHEMBL15610399 | 0.87 | HSP90AB1 (0.41) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL15609472 | 0.87 | HSP90B1 (0.42) | HSP90AA1HSP90AB1HSP90B1ERBB2 | |
| SCHEMBL12989255 | 0.87 | HSP90AB1 (0.43) | HSP90AA1HSP90AB1HSP90B1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.